Governance Enveric Biosciences, Inc.

ENVB

US29405E5050

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-13 pm EST			5-day change	1st Jan Change
2.100 ^USD	+3.96%		-11.39%	-42.15%

Jan. 29	Enveric Biosciences, Inc. Expands Collaboration with TOTEC Pharma Through Trademark License and Option	CI
Jan. 28	Enveric Biosciences announces closing of $1.5 million registered direct offering priced at-the-market under Nasdaq rules	RE

Executive Committee: Enveric Biosciences, Inc.

Manager

Positions heldSince

Joseph Tucker

58 year

Chief Executive Officer

2021-09-15

Kevin Coveney

63 year

Director of Finance/CFO

2023-03-12

Composition of the Board of Directors: Enveric Biosciences, Inc.

Director

CommitteesSince

Michael Webb

68 year

Audit Committee
Compensation Committee

George Kegler

71 year

Compensation Committee	2020-12-29
Governance Committee	2020-12-29
Nominating Committee	2020-12-29
Audit Committee Chair	2020-12-29

Frank Pasqualone

71 year

Audit Committee
Compensation Committee Chair	2022-07-12
Governance Committee Chair	2022-07-12
Nominating Committee Chair	2022-07-12

Marcus Schabacker

63 year

Governance Committee	2021-01-04
Nominating Committee	2021-01-04

Sheila DeWitt

66 year

Director/Board Member	2024-04-30
Independent Dir/Board Member	2024-04-30

Joseph Tucker

58 year

Director/Board Member

2021-09-15

Latest Appointments: Enveric Biosciences, Inc.

24-05-14	Firefly Neuroscience Names David Johnson Executive Chairman, Following WaveDancer Merger	MT
22-07-27	Enveric Biosciences, Inc. Appoints New Independent Directors	CI
22-07-19	Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines	CI
22-07-18	Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors	CI
22-06-15	Enveric Biosciences Announces Management Appointments	CI
22-05-04	Brad Thompson Resigns from the Board of Directors of Enveric Biosciences, Inc	CI
21-12-06	Enveric Biosciences, Inc. Announces Chief Medical Officer Changes	CI

More news

Former Officers and Directors: Enveric Biosciences, Inc.

Insider

Positions held

SinceUntil

Avani Kanubaddi

Chief Operating Officer	2020-12-01	2023-06-16
President	2021-11-14	2023-06-16

Lynn Gallant

Chief Tech/Sci/R&D Officer

2023-02-21

2023-04-30

Robert Dickey

Director of Finance/CFO

2022-09-05

2023-03-12

Ibrahim Dagher

Chief Tech/Sci/R&D Officer

2021-12-05

2022-12-31

David Ian Johnson

Chief Executive Officer	2021-01-04	2021-09-15
Chairman	2021-01-04	2022-10-27

Carter Ward

Director of Finance/CFO

2021-05-14

2022-07-01

Bevin O’Neil

Director/Board Member	2022-06-12	-
Independent Dir/Board Member	2022-06-12	-

Bradley Thompson

Director/Board Member	2021-08-31	2022-05-02
Independent Dir/Board Member	2021-08-31	2022-05-02

Robert G. Wilkins

Chief Tech/Sci/R&D Officer

2020-12-29

2021-11-28

John van Buiten

Director of Finance/CFO

2021-05-14

Douglas Lind

Director/Board Member	2021-03-16	-
Independent Dir/Board Member	2021-03-16	-

Solomon Mayer

Director/Board Member	2020-12-29	-
Independent Dir/Board Member	2020-12-29	-

Age distribution of managers

Parity Men Women

Male	9
Female	0

Of which Executive Committee

Male	2
Female	0

Of which Directors

Male	6
Female	0

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders. The Company, through Psybrary has created a robust intellectual property (IP) portfolio of new chemical entities for specific mental health indications. Its lead program, the EVM201 Series, comprises synthetic prodrugs of the active metabolite, psilocin. It is developing the first product from the EVM201 Series, EB-002, for the treatment of psychiatric disorders. The Company is also advancing its second program, the EVM301 Series, EB 003, which is an approach to the treatment of difficult-to-address mental health disorders. Within the Psybrary, it has three different types of molecules, Generation 1 (classic psychedelics), Generation 2 (pro-drugs), and Generation 3 (new chemical entities). It has created over 1,000 novel psychedelic molecular compounds and derivatives.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company